Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Moodys
Merck
McKesson
Dow

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IRINOTECAN HYDROCHLORIDE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Irinotecan Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00001495 A Phase I Study of Irinotecan (CPT-11) Administered as a Prolonged Infusion in Adult Patients With Solid Tumors Completed National Cancer Institute (NCI) Phase 1 1995-11-01 This study examines a 96 hour infusion schedule of irinotecan alternating with 72 hour drug-free intervals in patients with solid tumors in order to determine the maximum tolerated dose of this regimen.
NCT00002759 Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma Completed National Cancer Institute (NCI) Phase 1 1996-06-01 Phase I trial to study the effectiveness of irinotecan plus cyclosporine and phenobarbital in treating patients who have solid tumors or lymphoma that is refractory to standard therapy. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Cyclosporine and phenobarbital may enhance the effectiveness of irinotecan.
NCT00002902 Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors Completed National Cancer Institute (NCI) Phase 1 1997-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus ICI D1694 in treating patients with advanced solid tumors.
NCT00002902 Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors Completed University of Pennsylvania Phase 1 1997-04-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus ICI D1694 in treating patients with advanced solid tumors.
NCT00002933 Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer Completed National Cancer Institute (NCI) Phase 2 1996-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have metastatic or recurrent colorectal cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Irinotecan Hydrochloride

Condition Name

Condition Name for Irinotecan Hydrochloride
Intervention Trials
Colorectal Cancer 232
Metastatic Colorectal Cancer 115
Gastric Cancer 57
Pancreatic Cancer 50
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Irinotecan Hydrochloride
Intervention Trials
Colorectal Neoplasms 488
Adenocarcinoma 124
Pancreatic Neoplasms 109
Stomach Neoplasms 93
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Irinotecan Hydrochloride

Trials by Country

Trials by Country for Irinotecan Hydrochloride
Location Trials
United States 3,493
Canada 227
China 140
Japan 140
Italy 135
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Irinotecan Hydrochloride
Location Trials
California 193
New York 186
Texas 137
Illinois 130
Ohio 123
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Irinotecan Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Irinotecan Hydrochloride
Clinical Trial Phase Trials
Phase 4 10
Phase 3 124
Phase 2/Phase 3 23
[disabled in preview] 769
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Irinotecan Hydrochloride
Clinical Trial Phase Trials
Completed 518
Recruiting 248
Unknown status 111
[disabled in preview] 194
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Irinotecan Hydrochloride

Sponsor Name

Sponsor Name for Irinotecan Hydrochloride
Sponsor Trials
National Cancer Institute (NCI) 264
Pfizer 46
Amgen 31
[disabled in preview] 62
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Irinotecan Hydrochloride
Sponsor Trials
Other 1143
Industry 545
NIH 272
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Baxter
AstraZeneca
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.